PHAT

Phathom Pharmaceuticals, Inc.

10.61 USD
+0.01 (+0.09%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Phathom Pharmaceuticals, Inc. stock is up 52.88% since 30 days ago. The next earnings date is Mar 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 80% of the previous 4 February’s closed higher than January. In the last 4 Unusual Options Trades, there were 2 PUTs, 2 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
18 Jan 19:52 20 Dec, 2024 7.50 PUT 118 0
18 Jan 20:32 20 Dec, 2024 7.50 PUT 118 0
13 Feb 20:35 20 Dec, 2024 7.50 CALL 200 1044
15 Feb 14:40 20 Dec, 2024 7.50 CALL 200 1246

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.

  • Needham
    Fri Feb 16, 13:08
    buy
    confirm
  • Needham
    Fri Feb 9, 12:37
    buy
    confirm